Published in Ageing Res Rev on December 04, 2006
Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol (2009) 2.00
Innate immunity and aging. Exp Gerontol (2008) 1.73
Defective leukocyte GM-CSF receptor (CD116) expression and function in inflammatory bowel disease. Gastroenterology (2011) 1.73
Aging and innate immunity in the mouse: impact of intrinsic and extrinsic factors. Trends Immunol (2009) 1.49
G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.46
Leukocyte function in the aging immune system. J Leukoc Biol (2010) 1.32
Interleukin-5 priming of human eosinophils alters siglec-8 mediated apoptosis pathways. Am J Respir Cell Mol Biol (2007) 1.31
Aging and immune function: molecular mechanisms to interventions. Antioxid Redox Signal (2011) 1.18
Aging and its Impact on Innate Immunity and Inflammation: Implications for Periodontitis. J Oral Biosci (2014) 0.95
GM-CSF as successful salvage therapy of metamizole (dipyrone)-induced agranulocytosis with Fournier's gangrene and severe septic shock in an adolescent. Clin Case Rep (2016) 0.75
Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts. Hepatology (2011) 2.33
Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Int J Cancer (2004) 1.76
Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology (2009) 1.74
Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology (2008) 1.73
Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology (2009) 1.27
Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology (2010) 1.26
Inhibiting TGF-β signaling in hepatocellular carcinoma. Biochim Biophys Acta (2010) 1.20
Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol (2002) 1.17
Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clin Chim Acta (2007) 1.14
SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC. Int J Cancer (2005) 1.11
Quantitative determination of hepatitis C core antigen in therapy monitoring for chronic hepatitis C. Intervirology (2010) 1.08
Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer (2002) 1.05
Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma. Clin Cancer Res (2003) 1.04
Clinical role of tissue and serum levels of SCCA antigen in hepatocellular carcinoma. Int J Cancer (2005) 1.01
TLRs innate immunereceptors and Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) CIDR1α-driven human polyclonal B-cell activation. Acta Trop (2011) 0.99
Role of the alpha3beta1 and alpha6beta4 integrins in tumor invasion. Clin Exp Metastasis (2002) 0.97
APC-dependent impairment of T cell proliferation in aging: role of CD28- and IL-12/IL-15-mediated signaling. Mech Ageing Dev (2002) 0.96
Laminin-5 stimulates hepatocellular carcinoma growth through a different function of alpha6beta4 and alpha3beta1 integrins. Hepatology (2007) 0.95
Occurrence of portal vein tumor thrombus in hepatocellular carcinoma affects prognosis and survival. A retrospective clinical study of 150 cases. Hepatol Res (2002) 0.94
Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice. J Clin Gastroenterol (2006) 0.90
PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. Clin Dev Immunol (2011) 0.89
[An unusual case of transient loss of consciousness: the Fahr's syndrome]. Recenti Prog Med (2008) 0.89
Tissue expression of Squamous Cellular Carcinoma Antigen (SCCA) is inversely correlated to tumor size in HCC. Mol Cancer (2009) 0.88
Hepatic stellate cells stimulate HCC cell migration via laminin-5 production. Clin Sci (Lond) (2011) 0.88
Antifibrogenic effect of IFN-alpha2b on hepatic stellate cell activation by human hepatocytes. J Interferon Cytokine Res (2006) 0.87
HCC heterogeneity: molecular pathogenesis and clinical implications. Cell Oncol (2009) 0.87
Gelatinase expression at positive patch test reactions. Contact Dermatitis (2002) 0.86
ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. Biochem Pharmacol (2005) 0.85
MxA and PKR expression in chronic hepatitis C. J Interferon Cytokine Res (2004) 0.85
Case of multiple myeloma mimicking an infectious disease with fever, intrahepatic cholestasis, renal failure, and pulmonary insufficiency. Am J Hematol (2003) 0.84
Role of phosphoinositide 3-kinase and extracellular signal-regulated kinase pathways in granulocyte macrophage-colony-stimulating factor failure to delay fas-induced neutrophil apoptosis in elderly humans. J Gerontol A Biol Sci Med Sci (2006) 0.84
Kinase activation profile associated with TGF-β-dependent migration of HCC cells: a preclinical study. Cancer Chemother Pharmacol (2010) 0.84
The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. Curr Med Res Opin (2005) 0.84
PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma. Int J Cancer (2012) 0.83
Impaired interleukin-12-dependent T-cell functions during aging: role of signal transducer and activator of transcription 4 (STAT4) and suppressor of cytokine signaling 3 (SOCS3). J Gerontol A Biol Sci Med Sci (2006) 0.83
Gelatinase levels in male and female breast cancer. Biochem Biophys Res Commun (2002) 0.82
The TGF-β signaling pathway as a pharmacological target in a hepatocellular carcinoma. Curr Pharm Des (2012) 0.81
Involvement of ADAMs in tumorigenesis and progression of hepatocellular carcinoma: Is it merely fortuitous or a real pathogenic link? Biochim Biophys Acta (2010) 0.81
Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C. New Microbiol (2005) 0.81
Impairment of TLR7-dependent signaling in dendritic cells from chronic hepatitis C virus (HCV)-infected non-responders to interferon/ribavirin therapy. J Clin Immunol (2010) 0.80
EGFR and VEGFR as potential target for biological therapies in HCC cells. Cancer Lett (2008) 0.80
Palmodigital purpura as the only skin abnormality in myeloma-associated systemic amyloidosis. Br J Haematol (2003) 0.80
Role of defective ERK phosphorylation in the impaired GM-CSF-induced oxidative response of neutrophils in elderly humans. Mech Ageing Dev (2004) 0.78
[Syndrome of overlap: Chronic hepatitis C/autoimmune hepatitis: fact or fancy?]. Recenti Prog Med (2005) 0.77
Clinical role of serum and tissue matrix metalloprotease-9 expression in chronic HCV patients treated with pegylated IFN-alpha2b and ribavirin. J Interferon Cytokine Res (2005) 0.77
Asymptomatic systemic sarcoidosis arising 5 years after IFN-alpha treatment for chronic hepatitis C: a new challenge for clinicians. J Interferon Cytokine Res (2004) 0.76
[Multiple extrahepatic manifestations in a patient with chronic hepatitis C treated with interferon-alfa]. Recenti Prog Med (2004) 0.75
Proteolytic balance in patients with multiple sclerosis during interferon treatment. J Interferon Cytokine Res (2002) 0.75
[Extrapulmonary sarcoidosis with prevalent liver involvement: a new case and review of the literature]. Recenti Prog Med (2006) 0.75
[Clarkson syndrome: a rare clinical condition characterized by generalized edema associated to monoclonal gammopathy]. Recenti Prog Med (2005) 0.75
[Chronic hepatitis C/autoimmune hepatitis overlap syndrome: report of two cases]. Recenti Prog Med (2004) 0.75
Treatment of community-acquired pneumonia: a descriptive study in an Apulian department of internal medicine. Med Sci Monit (2005) 0.75
Glaucoma in primary amyloidosis: a fortuitous or causative association? Am J Med (2002) 0.75
[Diarrhea as first clinical manifestation of hepatocellular carcinoma]. Recenti Prog Med (2002) 0.75
[Hepatocellular carcinoma: tumoral or peritumoral disease?]. Recenti Prog Med (2007) 0.75